Rahman R - Search Results

1

Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma.

Youssef G, Rahman R, Bay C, Wang W, Lim-Fat MJ, Arnaout O, Bi WL, Cagney DN, Chang YS, Cloughesy TF, DeSalvo M, Ellingson BM, Flood TF, Gerstner ER, Gonzalez Castro LN, Guenette JP, Kim AE, Lee EQ, McFaline-Figueroa JR, Potter CA, Reardon DA, Huang RY, Wen PY. Youssef G, et al. Among authors: rahman r. J Clin Oncol. 2023 Jun 10;41(17):3160-3171. doi: 10.1200/JCO.22.01579. Epub 2023 Apr 7. J Clin Oncol. 2023. PMID: 37027809

2

Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.

Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY. Huang RY, et al. Among authors: rahman r. Cancer. 2013 Oct 1;119(19):3479-88. doi: 10.1002/cncr.28210. Epub 2013 Jul 2. Cancer. 2013. PMID: 23821555 Free article.

3

Spin-echo echo-planar perfusion prior to chemoradiation is a strong independent predictor of progression-free and overall survival in newly diagnosed glioblastoma.

Akgoz A, Rahman R, You H, Qu J, Hamdan A, Seethamraju RT, Wen PY, Young GS. Akgoz A, et al. Among authors: rahman r. J Neurooncol. 2014 Aug;119(1):111-9. doi: 10.1007/s11060-014-1454-x. Epub 2014 May 4. J Neurooncol. 2014. PMID: 24792644

4

Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.

Rahman R, Hamdan A, Zweifler R, Jiang H, Norden AD, Reardon DA, Mukundan S, Wen PY, Huang RY. Rahman R, et al. J Neurooncol. 2014 Aug;119(1):149-58. doi: 10.1007/s11060-014-1464-8. Epub 2014 May 8. J Neurooncol. 2014. PMID: 24805151

5

Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.

Rahman R, Hempfling K, Norden AD, Reardon DA, Nayak L, Rinne ML, Beroukhim R, Doherty L, Ruland S, Rai A, Rifenburg J, LaFrankie D, Alexander BM, Huang RY, Wen PY, Lee EQ. Rahman R, et al. Neuro Oncol. 2014 Nov;16(11):1523-9. doi: 10.1093/neuonc/nou118. Epub 2014 Jun 23. Neuro Oncol. 2014. PMID: 24958095 Free PMC article.

6

Incidence, risk factors, and reasons for hospitalization among glioblastoma patients receiving chemoradiation.

Rahman R, Catalano PJ, Reardon DA, Norden AD, Wen PY, Lee EQ, Nayak L, Beroukhim R, Dunn IF, Golby AJ, Johnson MD, Chiocca EA, Claus EB, Alexander BM, Arvold ND. Rahman R, et al. J Neurooncol. 2015 Aug;124(1):137-46. doi: 10.1007/s11060-015-1820-3. Epub 2015 Jun 2. J Neurooncol. 2015. PMID: 26033544

7

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.

Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. Huang RY, et al. Among authors: rahman r. Clin Cancer Res. 2016 Feb 1;22(3):575-81. doi: 10.1158/1078-0432.CCR-14-3040. Epub 2015 Oct 21. Clin Cancer Res. 2016. PMID: 26490307

8

Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab.

Chang K, Zhang B, Guo X, Zong M, Rahman R, Sanchez D, Winder N, Reardon DA, Zhao B, Wen PY, Huang RY. Chang K, et al. Among authors: rahman r. Neuro Oncol. 2016 Dec;18(12):1680-1687. doi: 10.1093/neuonc/now086. Epub 2016 May 4. Neuro Oncol. 2016. PMID: 27257279 Free PMC article.

9

Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab.

Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL. Grossmann P, et al. Among authors: rahman r. Neuro Oncol. 2017 Nov 29;19(12):1688-1697. doi: 10.1093/neuonc/nox092. Neuro Oncol. 2017. PMID: 28499022 Free PMC article. Clinical Trial.

10

The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. Vanderbeek AM, et al. Among authors: rahman r. Neuro Oncol. 2018 Jul 5;20(8):1034-1043. doi: 10.1093/neuonc/noy027. Neuro Oncol. 2018. PMID: 29518210 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,304 results

Search Page